Jan. 2025 – July 2025

At ENDO 2025 in San Francisco, study data showed that osteoporosis medications significantly reduce hospitalization and mortality even in patients over 80 years of age.

The osteoporosis drug Denosumab is being investigated for its potential to preserve beta cell function in the early stages of type 1 diabetes.
The trial is titled:
“A Phase 1/2 Prospective, Randomized, Double-blind, Placebo-controlled Multi-center Clinical Trial to Determine the Safety and Efficacy of Denosumab in Improving Beta Cell Function and Glycemic Control Among Patients With Type 1 Diabetes.”
https://clinicaltrials.gov/study/NCT06524960

To this end, a randomized, double-blind, placebo-controlled multicenter study is being conducted.

The FDA has approved several biosimilars of Denosumab (e.g., Stoboclo, Osenvelt) for the treatment of osteoporosis in postmenopausal women and for cancer-related bone involvement.